These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28151516)

  • 1. [Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention].
    Avogaro A
    G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):3S-12. PubMed ID: 28151516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From hyperglycemia to the risk of cardiovascular disease.
    Leiter LA
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control and cardiovascular mortality.
    Riddle MC
    Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):104-9. PubMed ID: 21522000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New antidiabetic medications: at the dawn of a revolution? New therapeutic options for type 2 diabetes are challenged for cardiovascular disease prevention].
    Crenier L
    Rev Med Brux; 2016; 37(4):349-355. PubMed ID: 28525236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antihyperglycaemic agents and cardiovascular disease: let's be optimistic.
    Pafili K; Rizzo M; Papanas N
    Curr Opin Cardiol; 2018 Jul; 33(4):444-454. PubMed ID: 29702499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cardiovascular complications of diabetes mellitus by aspirin.
    Nobles-James C; James EA; Sowers JR
    Cardiovasc Drug Rev; 2004; 22(3):215-26. PubMed ID: 15492769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes management: More than just cardiovascular risk?
    Zimmerman RS; Pantalone KM
    Cleve Clin J Med; 2014 Nov; 81(11):672-6. PubMed ID: 25368217
    [No Abstract]   [Full Text] [Related]  

  • 10. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):429-442. PubMed ID: 28121469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular safety of antidiabetics].
    Aline Roth PW; Jornayvaz FR
    Rev Med Suisse; 2016 Jun; 12(521):1084, 1086-8. PubMed ID: 27487675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials.
    Hopper I; Billah B; Skiba M; Krum H
    Eur J Cardiovasc Prev Rehabil; 2011 Dec; 18(6):813-23. PubMed ID: 21878448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA; Nicholls SJ; Lincoff AM
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.
    Alvarez CA; Lingvay I; Vuylsteke V; Koffarnus RL; McGuire DK
    Clin Pharmacol Ther; 2015 Aug; 98(2):145-61. PubMed ID: 25963811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton R
    Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EMPA-REG outcome study: critical appraisal and potential clinical implications.
    Perseghin G; Solini A
    Cardiovasc Diabetol; 2016 Jun; 15():85. PubMed ID: 27260022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist.
    Davidson MH
    Am J Cardiol; 2012 Nov; 110(9 Suppl):43B-49B. PubMed ID: 23062566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.